Oncotelic Therapeutics, Inc. Share Price
Equities
OTLC
US6283411097
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.042 USD | +2.94% | +6.60% | +9.66% |
Sales 2022 | - | Sales 2023 | 0.07 5.83 | Capitalization | 15.27M 1.27B |
---|---|---|---|---|---|
Net income 2022 | 5M 417M | Net income 2023 | -7M -583M | EV / Sales 2022 | - |
Net Debt 2022 | 11.02M 918M | Net Debt 2023 | 12.4M 1.03B | EV / Sales 2023 | 39,53,16,686 x |
P/E ratio 2022 |
4.5
x | P/E ratio 2023 |
-1.91
x | Employees | 22 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.17% |
1 day | +2.94% | ||
1 week | +6.60% | ||
Current month | +16.67% | ||
1 month | +16.67% | ||
3 months | +8.81% | ||
6 months | +45.83% | ||
Current year | +9.66% |
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/19/22 |
Director of Finance/CFO | 57 | 01/19/01 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06/20/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven W. King
BRD | Director/Board Member | 59 | 11/20/11 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/20/11 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/19/22 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.042 | +2.94% | 22,308 |
25/24/25 | 0.0408 | +7.37% | 10,259 |
24/24/24 | 0.038 | +5.56% | 8,648 |
23/24/23 | 0.036 | -8.63% | 8,356 |
22/24/22 | 0.0394 | 0.00% | 3,500 |
Delayed Quote OTC Markets, April 27, 2024 at 01:25 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+9.66% | 16.79M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- OTLC Stock